PGL was just way too expensive. Especially since the SPA was thrown out by the FDA. With no agreed endpoints for the trial, the risk has clearly increased.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025
